SCHEMBL3923592

SCHEMBL3923592

CSc1nccc(N(C)c2cc(-c3ccccc3)c3ncn(C)c3c2)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DPP4 P27487 1/20 0.37
▸ KDM4E B2RXH2 2/20 0.32
▸ NPSR1 Q6W5P4 2/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ POLB P06746 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ TDP1 Q9NUW8 1/20 0.32
▸ AKT1 P31749 3/20 0.31
▸ MAPK13 O15264 1/20 0.31
▸ MAPK12 P53778 1/20 0.31
▸ MAPK11 Q15759 1/20 0.31
▸ MAPK14 Q16539 1/20 0.31
▸ CSNK1E P49674 1/20 0.31
▸ PDE4A P27815 1/20 0.31
▸ IKBKB O14920 1/20 0.31
▸ CHUK O15111 1/20 0.31
▸ PDE10A Q9Y233 2/20 0.31
▸ AKT2 P31751 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3926834 0.85 LMNA (0.39) ALDH1A1POLBHPGDSMN1; SMN2PDE4A
SCHEMBL5947912 0.82 DPP4 (0.35) DPP4AKT1IKBKBCHUKPDE10A
SCHEMBL3933161 0.80 DPP4 (0.34) DPP4KDM4ENPSR1ALDH1A1POLB
SCHEMBL5320096 0.80 BRD4 (0.37) KDM4ENPSR1ALDH1A1POLBMAPT
SCHEMBL4004337 0.79 KDR (0.34) DPP4IKBKBCHUKKDR
SCHEMBL3924760 0.79 HRH4 (0.43) DPP4FGFR1KDREPHB4
SCHEMBL3935077 0.77 MAP3K5 (0.41) DPP4KDM4EALDH1A1MAPTSMN1; SMN2
SCHEMBL5948011 0.76 CCNE1 (0.48) AKT1MAPK13MAPK12AKT2FGFR1
SCHEMBL3927808 0.75 NPC1 (0.36) DPP4KDM4EALDH1A1MAPTSMN1; SMN2
SCHEMBL3924645 0.75 CCNE2 (0.45) IKBKBCHUKFGFR1KDREPHB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2041118-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE Amgen, Inc (US) 2009-04-01 — — EP disclosed
WO-2007114827-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2007-10-11 — — WO disclosed
WO-2007114827-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2007-10-11 — — WO disclosed
US-20060247263-A1 Substituted heterocyclic compounds and methods of use AMGEN INC. (US) 2006-11-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060247263-A1 Substituted heterocyclic compounds and methods of use MAPT, IAPP, MYLK2 DPP4 1381/4885KDM4E 4263/4885NPSR1 2529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback